Key result
Preinjury OAC therapy is linked to ~121% higher day 1 trauma mortality, mitigated by reversal.
Why the study?
Oral anticoagulant therapy increases bleeding risk, but its impact on trauma outcomes and the benefit of reversal remained uncertain.
Does preinjury oral anticoagulant therapy increase mortality in trauma patients, and does guideline-concordant reversal reduce this risk?
Cohort (n=27,426)
Yes
Does preinjury oral anticoagulant therapy increase mortality in trauma patients, and does guideline-concordant reversal reduce this risk?
Guideline-concordant reversal of oral anticoagulants in trauma patients significantly reduces early mortality without increasing thrombotic risk, though it remains underutilized.
Answers are grounded in this paper and cite their sources.
OAC reversal may lower trauma mortality without excess thrombosis; observational data leaves open need for RCTs before practice change.
Background: Oral anticoagulant (OAC) therapy increases bleeding risk but its impact on trauma outcomes and the benefit of reversal remains uncertain. This study aimed to evaluate 1/the effect of preinjury OAC therapy on trauma mortality and 2/the protective role of OAC reversal and its associated thrombotic risk. Methods: We conducted an observational study using a prospective multicenter trauma registry between January 2012 and December 2023. OAC-treated patients were matched with non-OAC-treated patients using a propensity score. Univariable and multivariable logistic regressions assessed associations between OAC therapy and day 1 and day 7 mortality. The effect of guideline-concordant OAC reversal was evaluated. Thrombotic complications were recorded. Findings: Of the 27,426 trauma patients, 3% were OAC-treated. They were older, had more comorbidities, and experienced higher mortality. After matching (n = 2196), OAC therapy remained independently associated with increased mortality (day 1: OR 2·21, 95% CI [1·41-3·43]; day 7: OR 2·06, [1·41-3·00]), with greater risk from vitamin K antagonists (VKA) than direct oral anticoagulants (DOAC). Guideline-concordant OAC reversal, achieved only in 21% of cases, independently reduced mortality at day 1 (OR 0·10, 95% CI [0·03-0·31], p < 0·01) and day 7 (OR 0·51, 95% CI [0·22-0·97], p < 0·01). No significant association was found between reversal and thrombotic complications. Interpretation: Preinjury OAC therapy substantially increased trauma mortality, particularly with VKA. Guideline-concordant reversal was associated with reduced mortality in both VKA- and DOAC-treated patients without excess thrombotic risk but remains underused. These findings emphasise the urgent need for systematic implementation of reversal strategies in OAC-treated trauma patients. Funding: The Traumabase registry is funded by several Regional Health Agencies (Agences Régionales de Santé, ARS): ARS Île-de-France, ARS Occitanie, ARS Grand Est, ARS Hauts-de-France, and ARS Auvergne-Rhône-Alpes. The registry is also funded by the French Road Safety Observatory-Road Safety Delegation Service (Observatoire National Interministériel de la Sécurité Routière-Délégation à la Sécurité Routière).
No takes yet. Share an insight, caveat, or question.
Lang et al. (2025) conducted a cohort in Trauma (n=27,426). Preinjury oral anticoagulant (OAC) therapy vs. No OAC therapy was evaluated on Day 1 mortality (OR 2.21, 95% CI 1.41-3.43). Preinjury oral anticoagulant therapy was associated with increased day 1 mortality (OR 2.21; 95% CI 1.41-3.43), whereas guideline-concordant reversal reduced day 1 mortality (OR 0.10; P<0.01).
Synapse has enriched 10 related papers. Consider them for comparative context: